| Literature DB >> 20508981 |
Yvonne Bol1, Annelien A Duits, Richel Lousberg, Raymond M M Hupperts, Michelle H P Lacroix, Frans R J Verhey, Johan W S Vlaeyen.
Abstract
Although fatigue is one of the most common and disabling symptoms in patients with multiple sclerosis (MS), its pathogenesis is still poorly understood and it is difficult to treat. The aim of the current study was to test the assumptions of a cognitive-behavioral model that explains fatigue and physical disability in MS patients, by comparing this approach with a more traditional biomedical approach. Structural equation modeling was applied to a sample of 262 MS patients. Neither the cognitive-behavioral, nor the biomedical model showed an adequate fit of our data. The modification indices supported an integration of both models, which showed a better fit than those of the separate models. This final model, is notable for at least three features: (1) fatigue is associated with depression and physical disability, (2) physical disability is associated with disease severity and fatigue-related fear and avoidance behavior, and (3) catastrophic interpretations about fatigue, fueled by depression, mediated the relationship between fatigue and fatigue-related fear and avoidance behavior. Our results suggest that an integrated approach, including the modification of catastrophic thoughts about fatigue, would be beneficial in the treatment of fatigue in MS patients.Entities:
Mesh:
Year: 2010 PMID: 20508981 PMCID: PMC2931636 DOI: 10.1007/s10865-010-9266-8
Source DB: PubMed Journal: J Behav Med ISSN: 0160-7715
Patient characteristics (n = 262)
| Gender (% male/% female) | 26/74 | |
| Age in years (mean, (SD)) | 47.6 (11.7) | Range 21.1–79.9 |
| Disease duration in years (mean, (SD)) | 8.6 (7.9) | Range 0.1–53.7 |
| Disease course (% RR, % SP, % PP) | 52/26/22 | |
| EDSS (mean, (SD)) | 4.0 (2.2) | Range 0–8 |
| HADS-depression (% <8/% ≥8) | 68/32 | |
| Use of disease modifying drugs (% yes, % no) | 43.5/56.5 | |
| Interferon (%) | 18.3 | |
| Glatiramer acetate (%) | 3.8 | |
| Other (%) | 15.3 | |
| Use of psychopharmaca (% yes, % no) | 26/74 | |
| Level of education (% low, % average, % high) | 28/36/36 | |
| Marital status (% partner/% no partner) | 78/22 | |
| Employment status (% working, % not working) | 30/70 |
RR Relapsing Remitting, SP Secondary Progressive, PP Primary Progressive, EDSS Expanded Disability Status Scale, HADS Hospital Anxiety and Depression Scale
Means, standard deviations (SD), range, Cronbach’s alpha’s (α) and Pearson-correlations of all measures
| Mean (SD) | Range | α | 2 | 3 | 4 | 5 | 6 | |
|---|---|---|---|---|---|---|---|---|
| 1. Disease severity (EDSS) | 4.0 (2.2) | 0–8 | – | 0.27** | 0.17* | 0.25** | 0.26** | –0.58** |
| 2. Fatigue (AFQ) | 19.8 (6.6) | 4–28 | 0.91 | – | 0.56** | 0.37** | 0.49** | –0.60** |
| 3. Catastrophizing about fatigue (FCS) | 20.4 (15.1) | 0–64 | 0.91 | – | – | 0.64** | 0.57** | –0.57** |
| 4. Fatigue-related fear and avoidance (TSK-F) | 37.9 (9.4) | 17–61 | 0.82 | – | – | – | 0.50** | –0.56** |
| 5. Depression (HADS-D) | 6.0 (4.2) | 0–21 | 0.83 | – | – | – | – | –0.57** |
| 6. Physical disability (SF-36) | 246.3 (87.0) | 15–390 | 0.91 | – | – | – | – | – |
EDSS Expanded Disability Status Scale, AFQ Abbreviated Fatigue Questionnaire, FCS Fatigue Catastrophizing Scale, TSK-F Fatigue Version of the Tampa Scale for Kinesiophobia, HADS Hospital Anxiety and Depression Scale, SF-36 Short Form Health Survey
* P < 0.01; ** P < 0.001
Goodness-of-fit summary for the models tested
| χ2 ( | RMSEA | GFI | AGFI | CFI | CAIC | |
|---|---|---|---|---|---|---|
| Model 1. Cognitive-behavioral model | 202.77(8)** | 0.305 | 0.814 | 0.512 | 0.709 | 288.16 |
| Model 2. Biomedical model | 107.76 (7)** | 0.235 | 0.902 | 0.706 | 0.85 | 199.71 |
| Model 1a: added | ||||||
| Disease severity to physical disability | 102.15 (7)** | 0.228 | 0.886 | 0.659 | 0.858 | 194.11 |
| Model 1b: added | ||||||
| Physical disability to depression | 52.54 (6)** | 0.172 | 0.94 | 0.789 | 0.931 | 151.06 |
| Model 1c: added | ||||||
| Depression to catastrophizing | 25.93 (5)** | 0.127 | 0.969 | 0.87 | 0.969 | 131.02 |
| Model 1d: added | ||||||
| Disease severity to fear-avoidance | 14.86 (4)* | 0.102 | 0.982 | 0.905 | 0.984 | 126.52 |
| Final model (model 3): deleted | ||||||
| Non-significant paths | 17.44 (6)* | 0.085 | 0.979 | 0.925 | 0.983 | 115.96 |
GFI Goodness-of-Fit Index, AGFI Adjusted Goodness-of-Fit Index, RMSEA Root Mean Square Error of Approximation, CFI Comparative Fit Index, CAIC Consistent Akaike Information Criteria
* P < 0.01; ** P < 0.001
Fig. 1Cognitive-behavioral model. Fear-Avoidance Fatigue-related fear and avoidance behavior, Catastrophizing catastrophizing about fatigue. Values shown are standardized regression coefficients. Explained variances are provided in parentheses. * p < .01; ** p < .0.001
Fig. 2Biomedical model. Fear-Avoidance Fatigue-related fear and avoidance behavior, Catastrophizing catastrophizing about fatigue. Values shown are standardized regression coefficients. Explained variances are provided in parentheses. * p < .01; ** p < .0.001
Fig. 3Final model. Fear-Avoidance Fatigue-related fear and avoidance behavior, catastrophizing catastrophizing about fatigue. Values shown are standardized regression coefficients. Explained variances are provided in parentheses. * p < .01; ** p < .0.001